Silihan lan utang jangka dawa perusahaan lifecore.com (LFCR)

Lifecore Biomedical (LFCR) utilizes robotic lines for sterile drug manufacturing to minimize human error. As a major contractor, the firm relies on predictive chemical inventory control to ensure process stability. Extensive laboratory networks support margins and ensure business resilience. The current metric stands at -0.31. The market trend below illustrates the dynamics of the company's long-term debt obligations.

LFCR Lifecore Biomedical Inc.: Utang jangka dawa perusahaan ing interval 28.04.2023 - 28.10.2026

Rincian metrik lan analitis perusahaan Lifecore Biomedical, Inc. (LFCR)

- rega lan prakiraan konsensus rega:

Rega saham Lifecore Biomedical Inc.|LFCR - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Lifecore Biomedical|LFCR - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi saben Saham Lifecore Biomedical|LFCR - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku lifecore.com|LFCR - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi Lifecore Biomedical|LFCR - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Lifecore Biomedical Inc.|LFCR - Gunggung utang perusahaan|Utang-utang marang nilai buku Lifecore Biomedical|LFCR - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Lifecore Biomedical

Pambiji fundamental:Lifecore Biomedical (LFCR)

Investors are seeking fundamental benchmarks in Lifecore Biomedical (LFCR) financial statements to assess business resilience. This metric measures total credit obligations with a maturity of over one year, reflecting the balance between investment development and debt load. Monitoring the issuer's long-term liabilities allows for an assessment of loan servicing risks. For Lifecore Biomedical, such funds are critical for establishing the costly cold chain infrastructure that ensures the safety of sterile injectables.

Perusahaan pesaing